The purpose of this study is to determine if the commonly administered chemotherapeutic agents including cisplatin, carboplatin, oxaliplatin, docetaxel and gemcitabine for solid tumors in clinical oncology, either a single format or given as combinations followed by surgery are effective in the treatment of relapsed and refractory non-small cell lung cancer patients.
Age ≤ 75 years with histologically proven NSCLC
No severe major organ dysfunction
WHO performance status of 0 or 1
No prior cancer chemotherapy
Age ≥ 76
Severe major organ dysfunction
WHO performance status of >1
Prior cancer chemotherapy
8
Treatment groupsSee each treatment group below.
Shanghai Jiao Tong University School of Medicine
Lead sponsor
Shanghai 10th People's Hospital
Collaborator
Jilin University
Collaborator
Jiangxi Provincial Cancer Hospital
Collaborator
Shanghai Tongji Hospital, Tongji University School of Medicine
Collaborator